TY - JOUR
T1 - EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)
AU - Tennvall, Jan
AU - Fischer, Manfred
AU - Bischof Delaloye, Angelika
AU - Bombardieri, Emilio
AU - Bodei, Lisa
AU - Giammarile, Francesco
AU - Lassmann, Michael
AU - Oyen, Wim
AU - Brans, Boudewijn
PY - 2007/4
Y1 - 2007/4
N2 - Background: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. Purpose: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.
AB - Background: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. Purpose: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.
KW - Y-ibritumomab tiuxetan
KW - Guidelines
KW - Non-Hodgkin's lymphoma
KW - Nuclear medicine
KW - Radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=33947273534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947273534&partnerID=8YFLogxK
U2 - 10.1007/s00259-007-0372-y
DO - 10.1007/s00259-007-0372-y
M3 - Article
C2 - 17323056
AN - SCOPUS:33947273534
VL - 34
SP - 616
EP - 622
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 4
ER -